Simris Group（SIMRIS B）株式概要シムリス・グループAB（PUBL）は、スウェーデン国内外において、微細藻類からの生物活性物質の開発、製造、販売を行っている。 詳細SIMRIS B ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6リスク分析キャッシュランウェイが1年未満である 過去5年間で収益は年間3.3%減少しました。 過去1年間で株主の希薄化は大幅に進んだ Swedish市場と比較して、過去 3 か月間の株価の変動が非常に大きい+2 さらなるリスクすべてのリスクチェックを見るSIMRIS B Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueSEK Current PriceSEK 0.08728.0k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-37m9m2016201920222025202620282031Revenue SEK 1.1mEarnings SEK 107.6kAdvancedSet Fair ValueView all narrativesSimris Group AB (PUBL) 競合他社New Nordic HealthbrandsSymbol: OM:NNHMarket cap: SEK 92.9mNicoccino HoldingSymbol: OM:NICOMarket cap: SEK 27.5mHumble GroupSymbol: OM:HUMBLEMarket cap: SEK 3.3bNosiumSymbol: NGM:NOSIUM BMarket cap: SEK 10.2m価格と性能株価の高値、安値、推移の概要Simris Group過去の株価現在の株価SEK 0.08752週高値SEK 0.2652週安値SEK 0.04ベータ0.841ヶ月の変化-0.46%3ヶ月変化20.83%1年変化23.93%3年間の変化-76.61%5年間の変化-90.73%IPOからの変化-99.37%最新ニュースReported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Net loss: kr6.19m (loss widened 3.2% from 1Q 2025).Reported Earnings • Mar 02Full year 2025 earnings released: kr0.043 loss per share (vs kr0.099 loss in FY 2024)Full year 2025 results: kr0.043 loss per share (improved from kr0.099 loss in FY 2024). Net loss: kr26.8m (loss narrowed 23% from FY 2024). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.お知らせ • Feb 28+ 4 more updatesSimris Group AB (PUBL) to Report Q3, 2026 Results on Nov 11, 2026Simris Group AB (PUBL) announced that they will report Q3, 2026 results on Nov 11, 2026お知らせ • Jan 20Simris Group AB (publ) Appoints Julian Read as a New Member of the BoardSimris Group AB (publ) at its EGM held on 19 January 2026 resolved to elect Julian Read as a new member of the board. The board now consists of Jonathan Royce, Frank Puccio, Magnus Högström, Hadrien Forterre, Richard Todd and Julian Read. Julian Read, born 1972, is a member of the board of directors and the managing director of Beyond the Border AB. Julian Read was previously the managing director of Simris Group and Doro AB. Julian Read holds a B.Sc. from Warwick University in Biology and Business.Reported Earnings • Nov 13Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr6.28m (loss narrowed 1.8% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Nov 10Simris Group Announces CEO ChangesThe Board of Directors of Simris Group has appointed Daniel Kubitza as interim CEO, effective 10 November 2025. Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and strategy development in the life sciences and healthcare industry. During Alexis Roberts-McIntosh’s nearly two years as CEO, Simris has made significant progress in refining its focus on the ADC-payload platform, including its lead candidate microcystin (MC)-based compound, SIMRIS-121.最新情報をもっと見るRecent updatesReported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Net loss: kr6.19m (loss widened 3.2% from 1Q 2025).Reported Earnings • Mar 02Full year 2025 earnings released: kr0.043 loss per share (vs kr0.099 loss in FY 2024)Full year 2025 results: kr0.043 loss per share (improved from kr0.099 loss in FY 2024). Net loss: kr26.8m (loss narrowed 23% from FY 2024). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.お知らせ • Feb 28+ 4 more updatesSimris Group AB (PUBL) to Report Q3, 2026 Results on Nov 11, 2026Simris Group AB (PUBL) announced that they will report Q3, 2026 results on Nov 11, 2026お知らせ • Jan 20Simris Group AB (publ) Appoints Julian Read as a New Member of the BoardSimris Group AB (publ) at its EGM held on 19 January 2026 resolved to elect Julian Read as a new member of the board. The board now consists of Jonathan Royce, Frank Puccio, Magnus Högström, Hadrien Forterre, Richard Todd and Julian Read. Julian Read, born 1972, is a member of the board of directors and the managing director of Beyond the Border AB. Julian Read was previously the managing director of Simris Group and Doro AB. Julian Read holds a B.Sc. from Warwick University in Biology and Business.Reported Earnings • Nov 13Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr6.28m (loss narrowed 1.8% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Nov 10Simris Group Announces CEO ChangesThe Board of Directors of Simris Group has appointed Daniel Kubitza as interim CEO, effective 10 November 2025. Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and strategy development in the life sciences and healthcare industry. During Alexis Roberts-McIntosh’s nearly two years as CEO, Simris has made significant progress in refining its focus on the ADC-payload platform, including its lead candidate microcystin (MC)-based compound, SIMRIS-121.Reported Earnings • Aug 14Second quarter 2025 earnings releasedSecond quarter 2025 results: Net loss: kr7.32m (loss narrowed 22% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.New Risk • Aug 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr89.4m (US$9.30m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 7.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Revenue is less than US$1m (kr2.5m revenue, or US$263k). Market cap is less than US$10m (kr89.4m market cap, or US$9.30m). Minor Risk Negative equity (-kr1.1m).お知らせ • May 29Simris Group AB (Publ) Appoints Richard Todd and Hadrien Forterre as New Members of the BoardSimris Group AB (publ) at its annual general meeting held on 28 May 2025, approved Richard Todd and Hadrien Forterre as new members of the board. Richard Todd holds a Master of Science in Immunology and a Master of Business Administration from Imperial College and the University of Birmingham. Richard currently serves as a Process Development and Digital Training Fellow at the University of Birmingham. Hadrien Forterre holds a Master of Laws from University Paris Nanterre and Duke University, and a Master of Business Administration from Columbia University. Hadrien currently also serves as vice president and general counsel at Pathify.New Risk • May 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 7.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Revenue is less than US$1m (kr2.5m revenue, or US$263k). Market cap is less than US$10m (kr48.6m market cap, or US$5.06m). Minor Risk Negative equity (-kr1.1m).Reported Earnings • May 15First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: kr5.99m (loss narrowed 35% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.お知らせ • Apr 28Simris Group AB (PUBL), Annual General Meeting, May 28, 2025Simris Group AB (PUBL), Annual General Meeting, May 28, 2025, at 16:00 W. Europe Standard Time. Location: at advokatfirman delphis, at naordenskioldsdgatan 11 a, malmo SwedenReported Earnings • Feb 27Full year 2024 earnings released: kr0.099 loss per share (vs kr0.16 loss in FY 2023)Full year 2024 results: kr0.099 loss per share (improved from kr0.16 loss in FY 2023). Net loss: kr34.6m (loss narrowed 7.2% from FY 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.New Risk • Feb 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr35m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Revenue is less than US$1m (kr4.6m revenue, or US$431k). Market cap is less than US$10m (kr44.7m market cap, or US$4.21m).お知らせ • Feb 26+ 3 more updatesSimris Group AB (PUBL) to Report Q2, 2025 Results on Aug 13, 2025Simris Group AB (PUBL) announced that they will report Q2, 2025 results on Aug 13, 2025Reported Earnings • Nov 14Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr6.39m (loss narrowed 16% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.お知らせ • Oct 19Simris Group Announces Board ChangesSimris Group announces that the company's major owner and chairman Steven Schapera has passed away after complications after surgery. Jonathan Royce for now takes over as chairman of the board of Simris Group AB.New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m (kr4.3m revenue, or US$424k). Market cap is less than US$10m (kr52.4m market cap, or US$5.11m). Minor Risk Shareholders have been diluted in the past year (45% increase in shares outstanding).Reported Earnings • Aug 15Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr9.42m (loss narrowed 10% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.お知らせ • Jun 28Simris Group AB (Publ) Appoints Jonathan Royce as Members of the BoardSimris Group AB (PUBL) at its annual general meeting held on June 28, 2024, approved the appointment of Jonathan Royce as members of the board. Jonathan Royce holds an MSc in Chemical Engineering from Northeastern University and has several years of experience in the life science industry with a particular specialisation in biotechnology. Jonathan Royce has previously been CEO of Bio-Works Technologies AB. Jonathan Royce is considered independent in relation to the Company and its management, as well as in relation to major shareholders in the Company.Board Change • Jun 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Robert Quandt was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • May 29Simris Group AB (publ) Announces Robert Quandt Declines Re-Election as Member of BoardSimris Group AB (publ) at its annual general meeting to be held on 28 June 2024, announced Robert Quandt has declined re-election as member of the board.お知らせ • May 17+ 2 more updatesSimris Group AB (PUBL) to Report Q3, 2024 Results on Nov 13, 2024Simris Group AB (PUBL) announced that they will report Q3, 2024 results on Nov 13, 2024お知らせ • May 01Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024.お知らせ • Mar 13Simris Group AB (PUBL) Announces CEO ChangesSimris Group AB has announced the appointment of Dr. Alexis Roberts-McIntosh, a highly experienced pharmaceutical industry executive, to the position of Group CEO. Alexis Roberts-McIntosh replaces current CEO Julian Read, who will be retained as an Advisor for a handover period of 3 months. Julian Read steps back from the Company in order to pursue other opportunities and will ensure a seamless transfer of knowledge to Alexis Roberts-McIntosh during the handover period. Dr. Roberts-McIntosh's appointment is an integral part of the strategic turnaround of the Simris Group's activities, which is underpinned by the shift in focus of the company from the low-margin and highly competitive dietary supplement space to the high-margin ADC payload pharmaceutical space - where the company's product has a sustainable competitive advantage underpinned by its broad patent protection. In the last 22 months considerable work has been done by outgoing CEO, Julian Read, to redefine Simris' corporate objectives, complete the acquisition of Cyano Biotech GmbH (since renamed Simris Biologics), and bring the Group substantially closer to securing its first ADC license agreement with a drug developer. These actions, combined with the funding support received from Simris Chairman Steven Schapera and other strategic shareholders, ensures that Dr. Roberts- McIntosh inherits a company that has a clear strategy, is operating efficiently, and is funded appropriately. Dr. Roberts-McIntosh holds a Ph.D in Medicinal Chemistry. She began her career with GlaxoSmithKline and has since spent the last 27 years transitioning upward through ever-more senior appointments at some of world's most iconic pharmaceutical companies including Pfizer, Johnson & Johnson, Reckitt Benckiser, and Abbott. She is highly entrepreneurial, has an unblemished record of driving innovative products to commercialisation, and has managed complex teams and large P&L's. By any measure, Alexis is an accomplished leader with a proven history of delivering outstanding sales growth with accompanying profitability.Reported Earnings • Feb 29Full year 2023 earnings released: kr0.11 loss per share (vs kr0.17 loss in FY 2022)Full year 2023 results: kr0.11 loss per share. Net loss: kr37.3m (loss widened 53% from FY 2022).Reported Earnings • Nov 09Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr7.57m (loss widened 27% from 3Q 2022).お知らせ • Nov 01Simris Group AB (PUBL) announced that it has received SEK 2.9295 million in fundingOn October 30, 2023, Simris Group AB (PUBL) closed the transaction. The transaction entails a dilution effect of approximately 3.2 per cent of the number of shares and votes in the company.Recent Insider Transactions • Sep 27Independent Chairman recently bought kr6.4m worth of stockOn the 22nd of September, Steven Schapera bought around 24m shares on-market at roughly kr0.27 per share. This transaction increased Steven's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of kr8.9m worth in shares.New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 88% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr47m free cash flow). Earnings have declined by 3.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Revenue is less than US$1m (kr1.8m revenue, or US$161k). Market cap is less than US$10m (kr82.7m market cap, or US$7.41m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).Recent Insider Transactions • Aug 11Independent Chairman recently bought kr55k worth of stockOn the 7th of August, Steven Schapera bought around 200k shares on-market at roughly kr0.28 per share. This transaction amounted to 2.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of kr163k worth in shares.お知らせ • Aug 03Simris Group AB Confirms New Patent Application from Its Adc-Payload PlatformSimris Group AB confirmed it has submitted a new patent application covering the optimisation of microcystin-based Antibody Drug Conjugate (ADC) payloads with a strongly improved efficacy and safety profile. Simris also confirms that its original method patent for modifying and producing payloads for ADCs, Antibody Antibiotic Conjugates (AACs) and beyond has now been granted in Israel. Simris' technology platform is currently fully patent protected in key markets including Europe, UK, USA, Australia, Japan, and Middle East.Reported Earnings • Jul 26Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: kr10.5m (loss widened 106% from 2Q 2022).お知らせ • May 09+ 2 more updatesSimris Alg AB (publ) to Report Q3, 2023 Results on Nov 08, 2023Simris Alg AB (publ) announced that they will report Q3, 2023 results on Nov 08, 2023Reported Earnings • Apr 20Full year 2022 earnings released: kr0.17 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.17 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 19Full year 2022 earnings released: kr0.14 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.14 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.分析記事 • Dec 22Is Simris Alg (STO:SIMRIS B) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Reported Earnings • Aug 21Second quarter 2022 earnings released: kr0.039 loss per share (vs kr0.092 loss in 2Q 2021)Second quarter 2022 results: kr0.039 loss per share (up from kr0.092 loss in 2Q 2021). Revenue: kr240.0k (down 71% from 2Q 2021). Net loss: kr5.11m (loss narrowed 29% from 2Q 2021).Recent Insider Transactions • May 17Interim Executive Chairman recently bought kr1.0m worth of stockOn the 11th of May, Steven Schapera bought around 3m shares on-market at roughly kr0.32 per share. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of kr1.2m worth in shares.Reported Earnings • Apr 27First quarter 2022 earnings released: kr0.051 loss per share (vs kr0.087 loss in 1Q 2021)First quarter 2022 results: kr0.051 loss per share (up from kr0.087 loss in 1Q 2021). Revenue: kr3.21m (up 430% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). Director Adam Springfeldt was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Apr 23First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr3.21m (up 431% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.お知らせ • Apr 23Simris Alg AB (publ) to Report Fiscal Year 2022 Results on Feb 15, 2023Simris Alg AB (publ) announced that they will report fiscal year 2022 results on Feb 15, 2023Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.36 loss per share (down from kr0.35 loss in FY 2020). Revenue: kr6.76m (up 196% from FY 2020). Net loss: kr28.4m (loss widened 11% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 15Third quarter 2021 earnings releasedThe company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr2.22m (up 102% from 3Q 2020). Net loss: kr10.7m (loss widened 108% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Nov 14Interim Executive Chairman recently bought kr149k worth of stockOn the 12th of November, Steven Schapera bought around 200k shares on-market at roughly kr0.75 per share. This was the largest purchase by an insider in the last 3 months. This was Steven's only on-market trade for the last 12 months.Executive Departure • Sep 23Chief Executive Officer Fredrika Gullfot has left the companyDuring their tenure, earnings grew by 20% annually compared to the industry average of 14%. Fredrika still personally held 1.28m shares (kr1.2m worth) as of June 2021. This is 1.6% of the company. Fredrika is the only executive to leave the company over the last 12 months.Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr819.0k (up 220% from 2Q 2020). Net loss: kr7.22m (loss widened 18% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 20Full year 2020 earnings released: kr0.60 loss per share (vs kr2.29 loss in FY 2019)Full year 2020 results: Net loss: kr25.6m (loss narrowed 4.9% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Feb 05New 90-day low: kr0.78The company is down 19% from its price of kr0.97 on 06 November 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.Is New 90 Day High Low • Sep 24New 90-day low: kr0.80The company is down 27% from its price of kr1.09 on 26 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 28% over the same period.お知らせ • Jul 17Simris Alg AB (publ) has completed a Composite Units Offering in the amount of SEK 29.074529 million.Simris Alg AB (publ) has completed a Composite Units Offering in the amount of SEK 29.074529 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 10,768,344 Price\Range: SEK 2.7 Transaction Features: Rights Offering株主還元SIMRIS BSE Personal ProductsSE 市場7D-13.9%1.9%2.0%1Y23.9%-7.3%9.9%株主還元を見る業界別リターン: SIMRIS B過去 1 年間で-7.3 % の収益を上げたSwedish Personal Products業界を上回りました。リターン対市場: SIMRIS B過去 1 年間で9.9 % の収益を上げたSwedish市場を上回りました。価格変動Is SIMRIS B's price volatile compared to industry and market?SIMRIS B volatilitySIMRIS B Average Weekly Movement21.5%Personal Products Industry Average Movement5.1%Market Average Movement6.3%10% most volatile stocks in SE Market13.3%10% least volatile stocks in SE Market3.7%安定した株価: SIMRIS Bの株価は、 Swedish市場と比較して過去 3 か月間で変動しています。時間の経過による変動: SIMRIS Bの weekly volatility ( 22% ) は過去 1 年間安定していますが、依然としてSwedishの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト20115Daniel Kubitzawww.simrisgroup.comシムリス・グループAB（PUBL）は、微細藻類からの生物活性物質の開発、製造、販売をスウェーデン国内外で行っている。スキンケア製品、医薬品、食品素材、オメガ3系EPA・DHA「Algae Omega-3」をSIMRISブランド名で提供している。2011年に法人化され、スウェーデンのハンメンホグに本社を置く。もっと見るSimris Group AB (PUBL) 基礎のまとめSimris Group の収益と売上を時価総額と比較するとどうか。SIMRIS B 基礎統計学時価総額SEK 135.65m収益（TTM）-SEK 27.00m売上高(TTM)SEK 2.65m44.4xP/Sレシオ-4.3xPER（株価収益率SIMRIS B は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SIMRIS B 損益計算書（TTM）収益SEK 2.65m売上原価-SEK 29.00k売上総利益SEK 2.68mその他の費用SEK 29.68m収益-SEK 27.00m直近の収益報告Mar 31, 2026次回決算日Aug 12, 2026一株当たり利益（EPS）-0.02グロス・マージン101.10%純利益率-1,020.52%有利子負債／自己資本比率0%SIMRIS B の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 19:37終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Simris Group AB (PUBL) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Net loss: kr6.19m (loss widened 3.2% from 1Q 2025).
Reported Earnings • Mar 02Full year 2025 earnings released: kr0.043 loss per share (vs kr0.099 loss in FY 2024)Full year 2025 results: kr0.043 loss per share (improved from kr0.099 loss in FY 2024). Net loss: kr26.8m (loss narrowed 23% from FY 2024). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
お知らせ • Feb 28+ 4 more updatesSimris Group AB (PUBL) to Report Q3, 2026 Results on Nov 11, 2026Simris Group AB (PUBL) announced that they will report Q3, 2026 results on Nov 11, 2026
お知らせ • Jan 20Simris Group AB (publ) Appoints Julian Read as a New Member of the BoardSimris Group AB (publ) at its EGM held on 19 January 2026 resolved to elect Julian Read as a new member of the board. The board now consists of Jonathan Royce, Frank Puccio, Magnus Högström, Hadrien Forterre, Richard Todd and Julian Read. Julian Read, born 1972, is a member of the board of directors and the managing director of Beyond the Border AB. Julian Read was previously the managing director of Simris Group and Doro AB. Julian Read holds a B.Sc. from Warwick University in Biology and Business.
Reported Earnings • Nov 13Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr6.28m (loss narrowed 1.8% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Nov 10Simris Group Announces CEO ChangesThe Board of Directors of Simris Group has appointed Daniel Kubitza as interim CEO, effective 10 November 2025. Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and strategy development in the life sciences and healthcare industry. During Alexis Roberts-McIntosh’s nearly two years as CEO, Simris has made significant progress in refining its focus on the ADC-payload platform, including its lead candidate microcystin (MC)-based compound, SIMRIS-121.
Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Net loss: kr6.19m (loss widened 3.2% from 1Q 2025).
Reported Earnings • Mar 02Full year 2025 earnings released: kr0.043 loss per share (vs kr0.099 loss in FY 2024)Full year 2025 results: kr0.043 loss per share (improved from kr0.099 loss in FY 2024). Net loss: kr26.8m (loss narrowed 23% from FY 2024). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings.
お知らせ • Feb 28+ 4 more updatesSimris Group AB (PUBL) to Report Q3, 2026 Results on Nov 11, 2026Simris Group AB (PUBL) announced that they will report Q3, 2026 results on Nov 11, 2026
お知らせ • Jan 20Simris Group AB (publ) Appoints Julian Read as a New Member of the BoardSimris Group AB (publ) at its EGM held on 19 January 2026 resolved to elect Julian Read as a new member of the board. The board now consists of Jonathan Royce, Frank Puccio, Magnus Högström, Hadrien Forterre, Richard Todd and Julian Read. Julian Read, born 1972, is a member of the board of directors and the managing director of Beyond the Border AB. Julian Read was previously the managing director of Simris Group and Doro AB. Julian Read holds a B.Sc. from Warwick University in Biology and Business.
Reported Earnings • Nov 13Third quarter 2025 earnings releasedThird quarter 2025 results: Net loss: kr6.28m (loss narrowed 1.8% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Nov 10Simris Group Announces CEO ChangesThe Board of Directors of Simris Group has appointed Daniel Kubitza as interim CEO, effective 10 November 2025. Daniel Kubitza has over 20 years of experience in corporate financing, commercialization and strategy development in the life sciences and healthcare industry. During Alexis Roberts-McIntosh’s nearly two years as CEO, Simris has made significant progress in refining its focus on the ADC-payload platform, including its lead candidate microcystin (MC)-based compound, SIMRIS-121.
Reported Earnings • Aug 14Second quarter 2025 earnings releasedSecond quarter 2025 results: Net loss: kr7.32m (loss narrowed 22% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
New Risk • Aug 06New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr89.4m (US$9.30m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 7.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Revenue is less than US$1m (kr2.5m revenue, or US$263k). Market cap is less than US$10m (kr89.4m market cap, or US$9.30m). Minor Risk Negative equity (-kr1.1m).
お知らせ • May 29Simris Group AB (Publ) Appoints Richard Todd and Hadrien Forterre as New Members of the BoardSimris Group AB (publ) at its annual general meeting held on 28 May 2025, approved Richard Todd and Hadrien Forterre as new members of the board. Richard Todd holds a Master of Science in Immunology and a Master of Business Administration from Imperial College and the University of Birmingham. Richard currently serves as a Process Development and Digital Training Fellow at the University of Birmingham. Hadrien Forterre holds a Master of Laws from University Paris Nanterre and Duke University, and a Master of Business Administration from Columbia University. Hadrien currently also serves as vice president and general counsel at Pathify.
New Risk • May 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr18m free cash flow). Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 7.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (80% increase in shares outstanding). Revenue is less than US$1m (kr2.5m revenue, or US$263k). Market cap is less than US$10m (kr48.6m market cap, or US$5.06m). Minor Risk Negative equity (-kr1.1m).
Reported Earnings • May 15First quarter 2025 earnings releasedFirst quarter 2025 results: Net loss: kr5.99m (loss narrowed 35% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • Apr 28Simris Group AB (PUBL), Annual General Meeting, May 28, 2025Simris Group AB (PUBL), Annual General Meeting, May 28, 2025, at 16:00 W. Europe Standard Time. Location: at advokatfirman delphis, at naordenskioldsdgatan 11 a, malmo Sweden
Reported Earnings • Feb 27Full year 2024 earnings released: kr0.099 loss per share (vs kr0.16 loss in FY 2023)Full year 2024 results: kr0.099 loss per share (improved from kr0.16 loss in FY 2023). Net loss: kr34.6m (loss narrowed 7.2% from FY 2023). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
New Risk • Feb 26New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr35m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings have declined by 7.1% per year over the past 5 years. Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Revenue is less than US$1m (kr4.6m revenue, or US$431k). Market cap is less than US$10m (kr44.7m market cap, or US$4.21m).
お知らせ • Feb 26+ 3 more updatesSimris Group AB (PUBL) to Report Q2, 2025 Results on Aug 13, 2025Simris Group AB (PUBL) announced that they will report Q2, 2025 results on Aug 13, 2025
Reported Earnings • Nov 14Third quarter 2024 earnings releasedThird quarter 2024 results: Net loss: kr6.39m (loss narrowed 16% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
お知らせ • Oct 19Simris Group Announces Board ChangesSimris Group announces that the company's major owner and chairman Steven Schapera has passed away after complications after surgery. Jonathan Royce for now takes over as chairman of the board of Simris Group AB.
New Risk • Oct 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr38m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 6.8% per year over the past 5 years. Revenue is less than US$1m (kr4.3m revenue, or US$424k). Market cap is less than US$10m (kr52.4m market cap, or US$5.11m). Minor Risk Shareholders have been diluted in the past year (45% increase in shares outstanding).
Reported Earnings • Aug 15Second quarter 2024 earnings releasedSecond quarter 2024 results: Net loss: kr9.42m (loss narrowed 10% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
お知らせ • Jun 28Simris Group AB (Publ) Appoints Jonathan Royce as Members of the BoardSimris Group AB (PUBL) at its annual general meeting held on June 28, 2024, approved the appointment of Jonathan Royce as members of the board. Jonathan Royce holds an MSc in Chemical Engineering from Northeastern University and has several years of experience in the life science industry with a particular specialisation in biotechnology. Jonathan Royce has previously been CEO of Bio-Works Technologies AB. Jonathan Royce is considered independent in relation to the Company and its management, as well as in relation to major shareholders in the Company.
Board Change • Jun 06Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Director Robert Quandt was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • May 29Simris Group AB (publ) Announces Robert Quandt Declines Re-Election as Member of BoardSimris Group AB (publ) at its annual general meeting to be held on 28 June 2024, announced Robert Quandt has declined re-election as member of the board.
お知らせ • May 17+ 2 more updatesSimris Group AB (PUBL) to Report Q3, 2024 Results on Nov 13, 2024Simris Group AB (PUBL) announced that they will report Q3, 2024 results on Nov 13, 2024
お知らせ • May 01Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024Simris Group AB (PUBL), Annual General Meeting, Jun 28, 2024.
お知らせ • Mar 13Simris Group AB (PUBL) Announces CEO ChangesSimris Group AB has announced the appointment of Dr. Alexis Roberts-McIntosh, a highly experienced pharmaceutical industry executive, to the position of Group CEO. Alexis Roberts-McIntosh replaces current CEO Julian Read, who will be retained as an Advisor for a handover period of 3 months. Julian Read steps back from the Company in order to pursue other opportunities and will ensure a seamless transfer of knowledge to Alexis Roberts-McIntosh during the handover period. Dr. Roberts-McIntosh's appointment is an integral part of the strategic turnaround of the Simris Group's activities, which is underpinned by the shift in focus of the company from the low-margin and highly competitive dietary supplement space to the high-margin ADC payload pharmaceutical space - where the company's product has a sustainable competitive advantage underpinned by its broad patent protection. In the last 22 months considerable work has been done by outgoing CEO, Julian Read, to redefine Simris' corporate objectives, complete the acquisition of Cyano Biotech GmbH (since renamed Simris Biologics), and bring the Group substantially closer to securing its first ADC license agreement with a drug developer. These actions, combined with the funding support received from Simris Chairman Steven Schapera and other strategic shareholders, ensures that Dr. Roberts- McIntosh inherits a company that has a clear strategy, is operating efficiently, and is funded appropriately. Dr. Roberts-McIntosh holds a Ph.D in Medicinal Chemistry. She began her career with GlaxoSmithKline and has since spent the last 27 years transitioning upward through ever-more senior appointments at some of world's most iconic pharmaceutical companies including Pfizer, Johnson & Johnson, Reckitt Benckiser, and Abbott. She is highly entrepreneurial, has an unblemished record of driving innovative products to commercialisation, and has managed complex teams and large P&L's. By any measure, Alexis is an accomplished leader with a proven history of delivering outstanding sales growth with accompanying profitability.
Reported Earnings • Feb 29Full year 2023 earnings released: kr0.11 loss per share (vs kr0.17 loss in FY 2022)Full year 2023 results: kr0.11 loss per share. Net loss: kr37.3m (loss widened 53% from FY 2022).
Reported Earnings • Nov 09Third quarter 2023 earnings releasedThird quarter 2023 results: Net loss: kr7.57m (loss widened 27% from 3Q 2022).
お知らせ • Nov 01Simris Group AB (PUBL) announced that it has received SEK 2.9295 million in fundingOn October 30, 2023, Simris Group AB (PUBL) closed the transaction. The transaction entails a dilution effect of approximately 3.2 per cent of the number of shares and votes in the company.
Recent Insider Transactions • Sep 27Independent Chairman recently bought kr6.4m worth of stockOn the 22nd of September, Steven Schapera bought around 24m shares on-market at roughly kr0.27 per share. This transaction increased Steven's direct individual holding by 3x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of kr8.9m worth in shares.
New Risk • Sep 15New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 88% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr47m free cash flow). Earnings have declined by 3.0% per year over the past 5 years. Shareholders have been substantially diluted in the past year (88% increase in shares outstanding). Revenue is less than US$1m (kr1.8m revenue, or US$161k). Market cap is less than US$10m (kr82.7m market cap, or US$7.41m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
Recent Insider Transactions • Aug 11Independent Chairman recently bought kr55k worth of stockOn the 7th of August, Steven Schapera bought around 200k shares on-market at roughly kr0.28 per share. This transaction amounted to 2.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of kr163k worth in shares.
お知らせ • Aug 03Simris Group AB Confirms New Patent Application from Its Adc-Payload PlatformSimris Group AB confirmed it has submitted a new patent application covering the optimisation of microcystin-based Antibody Drug Conjugate (ADC) payloads with a strongly improved efficacy and safety profile. Simris also confirms that its original method patent for modifying and producing payloads for ADCs, Antibody Antibiotic Conjugates (AACs) and beyond has now been granted in Israel. Simris' technology platform is currently fully patent protected in key markets including Europe, UK, USA, Australia, Japan, and Middle East.
Reported Earnings • Jul 26Second quarter 2023 earnings releasedSecond quarter 2023 results: Net loss: kr10.5m (loss widened 106% from 2Q 2022).
お知らせ • May 09+ 2 more updatesSimris Alg AB (publ) to Report Q3, 2023 Results on Nov 08, 2023Simris Alg AB (publ) announced that they will report Q3, 2023 results on Nov 08, 2023
Reported Earnings • Apr 20Full year 2022 earnings released: kr0.17 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.17 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 19Full year 2022 earnings released: kr0.14 loss per share (vs kr0.36 loss in FY 2021)Full year 2022 results: kr0.14 loss per share (improved from kr0.36 loss in FY 2021). Net loss: kr24.4m (loss narrowed 14% from FY 2021). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
分析記事 • Dec 22Is Simris Alg (STO:SIMRIS B) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Reported Earnings • Aug 21Second quarter 2022 earnings released: kr0.039 loss per share (vs kr0.092 loss in 2Q 2021)Second quarter 2022 results: kr0.039 loss per share (up from kr0.092 loss in 2Q 2021). Revenue: kr240.0k (down 71% from 2Q 2021). Net loss: kr5.11m (loss narrowed 29% from 2Q 2021).
Recent Insider Transactions • May 17Interim Executive Chairman recently bought kr1.0m worth of stockOn the 11th of May, Steven Schapera bought around 3m shares on-market at roughly kr0.32 per share. This was the largest purchase by an insider in the last 3 months. Steven has been a buyer over the last 12 months, purchasing a net total of kr1.2m worth in shares.
Reported Earnings • Apr 27First quarter 2022 earnings released: kr0.051 loss per share (vs kr0.087 loss in 1Q 2021)First quarter 2022 results: kr0.051 loss per share (up from kr0.087 loss in 1Q 2021). Revenue: kr3.21m (up 430% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.
Board Change • Apr 27No independent directorsThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 10 experienced directors. No highly experienced directors. No independent directors (11 non-independent directors). Director Adam Springfeldt was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Apr 23First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr3.21m (up 431% from 1Q 2021). Net loss: kr4.03m (loss narrowed 41% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
お知らせ • Apr 23Simris Alg AB (publ) to Report Fiscal Year 2022 Results on Feb 15, 2023Simris Alg AB (publ) announced that they will report fiscal year 2022 results on Feb 15, 2023
Reported Earnings • Feb 17Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: kr0.36 loss per share (down from kr0.35 loss in FY 2020). Revenue: kr6.76m (up 196% from FY 2020). Net loss: kr28.4m (loss widened 11% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 61% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 15Third quarter 2021 earnings releasedThe company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr2.22m (up 102% from 3Q 2020). Net loss: kr10.7m (loss widened 108% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Nov 14Interim Executive Chairman recently bought kr149k worth of stockOn the 12th of November, Steven Schapera bought around 200k shares on-market at roughly kr0.75 per share. This was the largest purchase by an insider in the last 3 months. This was Steven's only on-market trade for the last 12 months.
Executive Departure • Sep 23Chief Executive Officer Fredrika Gullfot has left the companyDuring their tenure, earnings grew by 20% annually compared to the industry average of 14%. Fredrika still personally held 1.28m shares (kr1.2m worth) as of June 2021. This is 1.6% of the company. Fredrika is the only executive to leave the company over the last 12 months.
Reported Earnings • Aug 21Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr819.0k (up 220% from 2Q 2020). Net loss: kr7.22m (loss widened 18% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 20Full year 2020 earnings released: kr0.60 loss per share (vs kr2.29 loss in FY 2019)Full year 2020 results: Net loss: kr25.6m (loss narrowed 4.9% from FY 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Feb 05New 90-day low: kr0.78The company is down 19% from its price of kr0.97 on 06 November 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 11% over the same period.
Is New 90 Day High Low • Sep 24New 90-day low: kr0.80The company is down 27% from its price of kr1.09 on 26 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Personal Products industry, which is up 28% over the same period.
お知らせ • Jul 17Simris Alg AB (publ) has completed a Composite Units Offering in the amount of SEK 29.074529 million.Simris Alg AB (publ) has completed a Composite Units Offering in the amount of SEK 29.074529 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 10,768,344 Price\Range: SEK 2.7 Transaction Features: Rights Offering
